[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100460869":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":22,"centralContacts":26,"locations":32,"responsibleParty":54,"collaborators":57,"id":63,"slug":64,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":30,"eligibilityCriteria":69,"healthyVolunteers":65,"sex":70,"minAge":71,"maxAge":30,"enrollmentInfo":72,"targetDuration":30,"studyType":75,"phases":76,"briefSummary":78,"conditions":79,"keywords":86,"overallStatus":34,"whyStopped":30,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":97},{"fullName":5,"class":6},"Beth Israel Deaconess Medical Center","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"AVECURE FLEXIBLE MICROWAVE ABLATION PROBE FOR LUNG NODULES","EXPERIMENTAL","The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits.\n\n* Ablation Procedure- MWA will be used to treat solitary pulmonary nodules up to 3cm.\n* CT scan will then be performed to evaluate the radiological changes 2 - 4 weeks after the ablation procedure.\n* Surgery will be performed to remove the lung nodule and the tissue will be evaluated by pathology.",[13],"Device: AveCure 16 Gauge Flexible Microwave Ablation Probe",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DEVICE","AveCure 16 Gauge Flexible Microwave Ablation Probe","Microwave ablation of the solitary pulmonary nodule will be performed through a bronchoscopic approach using the AveCure Flexible Microwave Ablation Probe before surgery",[9],[21],"Avecure",[23],{"name":24,"affiliation":5,"role":25},"Jason Beattie, MD","PRINCIPAL_INVESTIGATOR",[27],{"name":24,"role":28,"phone":29,"phoneExt":30,"email":31},"CONTACT","(617) 632- 8252",null,"jbeattie@bidmc.harvard.edu",[33],{"facility":5,"status":34,"city":35,"state":36,"zip":37,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"RECRUITING","Boston","Massachusetts","02115","United States","US",{"type":41,"coordinates":42},"Point",[43,44],-71.05977,42.35843,{"lat":44,"lon":43},[47,50,52],{"name":48,"role":49,"phone":30,"phoneExt":30,"email":30},"Adnan Majid, MD","SUB_INVESTIGATOR",{"name":51,"role":49,"phone":30,"phoneExt":30,"email":30},"Mihir S Parikh, MD",{"name":53,"role":25,"phone":30,"phoneExt":30,"email":30},"Beattie Jason, MD",{"type":25,"investigatorFullName":55,"investigatorTitle":56,"investigatorAffiliation":5,"oldNameTitle":30,"oldOrganization":30},"Jason A Beattie","Principal Investigator",[58,61],{"name":59,"class":60},"MedWaves, Inc","UNKNOWN",{"name":62,"class":6},"Dana-Farber Cancer Institute","100460869","avecure-flexible-microwave-ablation-probe-for-lung-nodules-100460869",false,"NCT05281237","Avecure Flexible Microwave Ablation Probe For Lung Nodules","Feasibility and Efficacy of the AveCure Flexible Microwave Ablation Probe for Peripheral Lung Nodule","Inclusion Criteria:\n\n* Subject with Stage I - II primary lung cancer (Solitary nodules up to 3 cm) as defined by previous pathology or ROSE.\n* Pathological proof of target nodule\u002Ftumor type and malignancy with specimen considered adequate per institutional laboratory standards\n* Target nodule\u002Ftumor which can be accessed via navigational bronchoscopy and confirmed location with cone beam CT scan intra-operatively\n* Resection\u002Fsurgical candidate (lobectomy or greater)\n* Participants must be at least 22 years old and able to provide consent\n\nExclusion Criteria:\n\n* Subjects in whom flexible bronchoscopy is contraindicated\n* Target nodule \\\u003C 1.0 cm\n* Prior radiation or neo adjuvant chemotherapy of the target nodule\u002Ftumor\n* Any comorbidity that the investigator feels would interfere with the safety of the subject or the evaluation of study objectives\n* Pacemaker, implantable cardioverter, or another electronic implantable device\n* Patient cannot tolerate bronchoscopy\n* Patients with coagulopathy\n* Patients in other therapeutic lung cancer studies\n* Subject is pregnant or breastfeeding\n* COVID-19 positive patient at the time of procedure.","ALL","22 Years",{"count":73,"type":74},10,"ESTIMATED","INTERVENTIONAL",[77],"NA","This research study to determine the effectiveness of the AveCure Flexible Microwave Ablation Probe to destroy cancerous lung nodules up to 3 c m in size.\n\nThis research study involves microwave ablation (MWA)",[80,81,82,83,84,85],"Stage I - II Primary Lung Cancer","Stage I Lung Cancer","Stage II Lung Cancer","Lung Cancer Stage I","Lung Cancer Stage II","Lung Cancer",[87,81,82,83,84,85],"Stage I - II primary lung cancer","2026-04-07",{"date":90,"type":91},"2026-04-08","ACTUAL",{"date":93,"type":91},"2022-06-01",{"date":95,"type":74},"2027-06-30",{"name":5,"class":6},1]